Text|Far Mountain
Editor|Multifish
- Before reading this article, I sincerely invite you to click "Follow", which is convenient for you to discuss and share, and brings you a different sense of participation, thank you for your support.
During the epidemic, in order to cope with the needs of large-scale nucleic acid testing, nucleic acid testing companies came into being, and the business was very hot. However, these enterprises are born in a special environment, and they must gradually disappear with the end of the special environment.
Now I heard that many nucleic acid testing companies have begun to collectively litigate to collect debts, and the "hidden dangers" have appeared, and they have been reduced to collecting debts everywhere.
Daan Gene is a large nucleic acid testing company, and now it is also going to court with 4 laboratories because of economic problems, let's take a look at what is going on.
In order to control the spread of the epidemic for three years, large-scale nucleic acid testing is considered to be one of the effective means. However, frequent large-scale nucleic acid testing cannot rely only on the power of hospitals, so many nucleic acid testing companies have emerged.
In the past 3 years, these nucleic acid testing companies have made a lot of money, and even some companies have increased their revenue by 30 times and their profits by 300 times, even criminals will be surprised when they see such data.
Daan Gene has also achieved rapid development in the epidemic, they mainly sell testing reagents, the revenue in three years is 5.341 billion yuan, 7.664 billion yuan and 12.064 billion yuan, and the profit is 2.449 billion yuan, 3.618 billion yuan and 5.412 billion yuan respectively.
However, the operation is getting better and better, but the company is also facing a very real problem, the accounts receivable cannot be collected, the collection is slow or there is no payment at all. The money was lying on the bills, which was unacceptable to Daan Gene, and they had to file a lawsuit to collect the debt.
The data shows that by the end of last year, Daan Gene's accounts receivable were 4.065 billion, accounting for 48.4% of the total revenue, which means that almost half of the money was not available. Of this money, more than 500 million are bad debts, and there is basically no hope of getting it.
The debt was too high, and Daan Gene had no choice, so it had to take the customer who owed the debt to court, but the effect was not ideal.
With the end of large-scale nucleic acid testing, many companies have written off the company at the first time, and the company's controlling person has also been restricted from high consumption due to economic problems, obviously even if it can win in court, it is difficult to get these money.
Daan Gene is not alone, in fact, other companies of the same type are also facing the same problem, and it is difficult to recover accounts receivable.
Some company leaders said that if they can pay back within a year, it is good, because many customers have no sign of repaying even after a year.
After 2020, the business of nucleic acid testing is very hot, and many laboratories have appeared, but those who can get this business are not ordinary people, because they basically have relationships with relevant departments, or get them from people who have relationships.
If the era of large-scale nucleic acid testing is not over, the two sides are still in cooperation, these laboratories have no problem with payment, but now there is no such business, many laboratories have closed, for such partners, genetic testing companies want to get the arrears, the difficulty can be imagined.
Paper receivables put a lot of pressure on many companies. The demand for nucleic acid testing in the epidemic is very large, and many companies have made a lot of money relying on this business.
Because the settlement process of this business is more complicated, it is normal to have a long payment cycle, which leads to a lot of money on the books of many companies.
For example, a company in Lanzhou generated revenue of 2.061 billion yuan in the first half of last year, but 2 billion yuan was not received, which is very unhealthy for the company's finances. How to recover the arrears is a big problem faced by these enterprises.
It is no longer possible to rely on nucleic acid testing to make quick money, and these companies have not been able to recover their funds, what should they do in the future? For some emerging companies, they may have to make difficult decisions about whether to close their doors or find a new direction for their business.
If they can find a new business direction, these companies can survive, otherwise they will basically have to close their doors.
In addition, some genetic testing companies have made a bad impression on the whole society, which has also brought great difficulties to the operation of emerging companies. Of course, those who have a way out can do something else.
For example, it is reported that a nucleic acid testing company has entered the housing rental market, although there is no relationship between the two businesses, but it does not affect the company's operation at all, it seems that the actual controller of this company is indeed very energetic.
For established companies, they have a business that they rely on before, such as BGI's fetal genetic testing business, which relies on this business to make a good fortune and perform very well in the stock market.
For companies like BGI, the nucleic acid testing business is gone, or reduced, but it is to return their main business to normal, which will not have much impact on the company's operation.
In the past few years, nucleic acid testing companies have made a lot of money, but some companies have made money that is unconscionable. Should these businesses be sympathetic if the receivables are not received?
What do you have to say about this? Welcome to leave your opinion in the comment area!